cosmic-313 points to first-line triplet option for advanced rcc | toni choueiri
Published 1 year ago • 295 plays • Length 2:53Download video MP4
Download video MP3
Similar videos
-
1:49
cosmic-313: cabozantinib with nivolumab and ipilimumab in untreated arcc
-
4:06
cosmic-313 trial results and implications for triplet rcc therapy
-
2:56
#esmo22 highlights on cabozantinib with nivo and ipi for intermediate/poor risk adv. rcc: cosmic-313
-
4:01
cosmic-313: cabo nivo ipi in 1l advanced rcc of imdc intermediate or poor risk
-
2:16
highlights in mrcc from esmo 2022 - (cosmic-313 trial)
-
3:56
phase ii trial of pembrolizumab & cabozantinib in patients with recurrent metastatic hnscc
-
5:10
real-world treatment outcomes of 1l axitinib pembrolizumab in patients with advanced rcc in the us
-
1:28:18
navigating evolving standards of care in rcc: novel targeted and immunotherapy options
-
3:03
adjuvant pembrolizumab improves rcc disease-free survival | toni choueiri
-
4:22
cabozantinib in combination w/ nivolumab and ipilimumab of imdc intermediate or poor risk signif...
-
0:41
dr. toni choueiri on cabozantinib and nivolumab combination in kidney cancer
-
6:50
esmo 2022: renal roundup
-
1:40
phase iii meteor trial: cabozantinib vs everolimus for advanced clear cell renal cell carcinoma
-
1:35
dr. toni choueiri on cabozantinib versus everolimus in renal cell carcinoma
-
4:24
researcher comment: the savoir trial | toni choueiri
-
3:49
cabozantinib benefit for metastatic papillary rcc demonstrated | sumanta pal
-
2:34
nivo cabozantinib vs sunitinib for first-line treatment of arcc
-
4:23
esmo22: cabozantinib in combination with nivo & ipi in previously untreated arcc of imdc interme...
-
4:05
long-term rcc data with nivolumab
-
25:09
kidney cancer highlights from esmo 2022